Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHUK | O15111 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21896052 | 0.73 | CHUK (0.43) | CHUK | |
| SCHEMBL17500018 | 0.72 | CHUK (0.42) | CHUK | |
| SCHEMBL25722173 | 0.71 | — | — | |
| SCHEMBL13833608 | 0.70 | CHUK (0.43) | CHUK | |
| SCHEMBL13833443 | 0.69 | — | — | |
| SCHEMBL22788995 | 0.68 | CHUK (0.38) | CHUKKMT2ACYP2A6 | |
| SCHEMBL6311834 | 0.68 | CHUK (0.71) | CHUK | |
| SCHEMBL26232177 | 0.67 | TYMS (0.41) | KMT2A | |
| SCHEMBL1179741 | 0.66 | CYP2A6 (0.34) | KMT2ACYP2A6 | |
| SCHEMBL13215451 | 0.66 | PDK2 (0.43) | CHUKKMT2ACYP2A6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| US-6962920-B2 | Pyrimidine derivatives and methods of making and using these derivatives | DUQUESNE UNIVERSITY OF THE HOLY GHOST (US) | 2005-11-08 | — | — | US | disclosed |
| US-20040039000-A1 | Novel pyrimidine derivatives and methods of making and using these derivatives | GANGJEE ALEEM (US) | 2004-02-26 | — | — | US | disclosed |
| US-6696455-B1 | NITROGEN COMPOUNDS SUCH AS 6-CHLORO-2-METHYL-4-OXO-PYRIDO (3,2-D)PYRIMIDINE USED AS ANTICARCINOGENIC AGENTS AND/OR FOR PROPHYLAXIS OF INFECTIONS CAUSED BY PNEUMOCYSTIS OR TOXOPLASMA | DUQUESNE UNIVERSITY OF THE HOLY GHOST | 2004-02-24 | — | — | US | disclosed |
| US-20030144509-A1 | Pyrimidine derivatives and methods of making and using these derivatives | GANGJEE ALEEM (US) | 2003-07-31 | — | — | US | disclosed |
| US-6537999-B2 | Furopyrimidines and pyrrolopyrimidines; treating cancer, and secondary infections caused by Pneumocystis carinii and Toxoplasmosis gondii in immunocompromised patients. | DUQUESNE UNIVERSITY OF THE HOLY GHOST | 2003-03-25 | — | — | US | disclosed |
| US-6518426-B1 | Novel pyrrolo(3,2-d)pyrimidine derivatives of the following general formula compounds are useful in the treatment of bacterial infections such as Toxoplasmosis gondii and Pneumocystis carinii, and various types of cancer, | DUQUESNE UNIVERSITY OF THE HOLY GHOST | 2003-02-11 | — | — | US | disclosed |
| US-6420370-B1 | ANTITUMOR, ANTIBIOTIC, ANTIMALARIAL, ANTIFUNGAL OR ANTIPROTOZOAL AGENTS, OR AS SYNERGISTIC AGENTS ENZYME INHIBITORS | DUQUESNE UNIVERSITY OF THE HOLY GHOST | 2002-07-16 | — | — | US | disclosed |
| US-20020052384-A1 | Novel pyrimidine derivatives and methods of making and using these derivatives | GANGJEE ALEEM (US) | 2002-05-02 | — | — | US | disclosed |
| US-6221872-B1 | DEBROMINATING A PYRROLE; FUSING THE PRODUCT WITH AN AMIDINE; CONDENSING THE PRODUCT WITH A NUCLEOPHILE; REDUCING AND PURIFYING | DUQUESNE UNIVERSITY OF THE HOLY GHOST | 2001-04-24 | — | — | US | disclosed |
| US-6103727-A | RESISTING AND TREATING PNEUNOCYSTIS CARINII AND TOXOPLASMOSIS GONDII INFECTIONS IN IMMUNOCOMPROMISED PATIENTS; AUTOMIMMUNE DISEASES; AIDS; ANTICARCINOGENIC,-TUMOR,-PROTAZOA AGENTS; MALARIA; FUNGICIDES; SYNERGISTIC WITH SULFONAMIDES | DUQUESNE UNIVERSITY OF THE HOLY GHOST (US) | 2000-08-15 | — | — | US | disclosed |
| US-6096750-A | Furopyrimidines and methods of making and using the same derivatives | DUQUESNE UNIVERSITY OF THE HOLY GHOST (US) | 2000-08-01 | — | — | US | disclosed |
| US-6077844-A | FOR TREATING ILLNESSES SUCH AS CANCER, AND SECONDARY INFECTIONS CAUSED BY PNEUMOCYSTIS CARINII AND TOXOPLASMOSIS GONDII IN IMMUNOCOMPROMISED PATIENTS | DUQUESNE UNIVERSITY OF THE HOLY GHOST (US) | 2000-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040039000-A1 | Novel pyrimidine derivatives and methods of making and using these derivatives | TYMP, TYMS, DPYD | CHUK 341/4885KMT2A 2154/4885CYP2A6 535/4885 |
| US-20020052384-A1 | Novel pyrimidine derivatives and methods of making and using these derivatives | TYMP, TYMS, DPYD | CHUK 341/4885KMT2A 2154/4885CYP2A6 535/4885 |
| US-20030144509-A1 | Pyrimidine derivatives and methods of making and using these derivatives | TYMS, TYMP, DPYD | CHUK 139/4885KMT2A 1423/4885CYP2A6 1037/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.